Predictors of functional benefit of hepatitis C therapy in a ‘real-life’ cohort

Table 1 Baseline characteristics of the study population

Demographics	Value
Age (yr)	59 ± 10 (27-83)
Male gender	133 (67)
HCV genotype
1a	47 (23)
1b	100 (50)
1 (no confirmed subtype)	9 (5)
2	7 (4)
3	30 (15)
4	6 (3)
Viral load 106 (IU/mL)	2.04 ± 3.46 (0.01-34.50)
Treatment history
Treatment naive	86 (43)
Treatment experienced	113 (57)
Protease inhibitor experienced	8 (4)
Liver/renal status
Platelets (103/μL)	116 ± 61 (26-341)
Total bilirubin (mg/dL)	1.4 ± 0.9 (0.2-5.7)
INR	1.34 ± 0.78 (0.40-5.70)
Creatinine (mg/dL)	0.80 ± 0.22 (0.43-1.96)
TE score (kPa)1	24.5 ± 12.5 (5.5-75)
Average MELD score	9 ± 3 (6-23)
MELD score
< 10	130 (65)
10-15	59 (30)
> 15	10 (5)
Child-Pugh score
A	152 (76)
B	40 (20)
C	7 (4)

Data are expressed as n (%) or means ± SD (range).

¹Data available for 112 patients.